Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Accured Expenses (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Change in Accured Expenses data on record, last reported at $47.7 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 309.85% year-over-year to $47.7 million; the TTM value through Dec 2025 reached $45.4 million, up 1660.63%, while the annual FY2025 figure was $45.4 million, 1660.63% up from the prior year.
  • Change in Accured Expenses reached $47.7 million in Q4 2025 per TARS's latest filing, up from -$15.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $47.7 million in Q4 2025 and bottomed at -$22.7 million in Q4 2024.
  • Average Change in Accured Expenses over 5 years is $3.1 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: soared 3168.48% in 2021, then plummeted 744.13% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $357000.0 in 2021, then plummeted by 232.49% to -$473000.0 in 2022, then surged by 845.45% to $3.5 million in 2023, then tumbled by 744.13% to -$22.7 million in 2024, then soared by 309.85% to $47.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $47.7 million in Q4 2025, -$15.9 million in Q3 2025, and $19.5 million in Q2 2025.